ArticleVaccines2023
Efficacy of Phase I and Phase II
Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Prevalence and Risk Factors of Q Fever in Smallholder Dairy Farms in Kenya.Veterinary medicine and science · 2026Article
- Systems biology approach unveils the cellular and molecular mechanisms of formalin-inactivated whole cell vaccine-induced protective immunity againstFrontiers in immunology · 2026Article
- Real-Time Auto-Monitoring of Livestock: Quantitative Framework and Challenges.Sensors (Basel, Switzerland) · 2025Review
- Overview of the Q fever vaccine development: current status and future prospects.Antonie van Leeuwenhoek · 2025Review
- Navigating Q fever: Current perspectives and challenges in outbreak preparedness.Open veterinary journal · 2024Review
- Article
- Efficacy and Safety of an Inactivated Phase IAnimals : an open access journal from MDPI · 2024Review
- Q fever immunology: the quest for a safe and effective vaccine.NPJ vaccines · 2023Review
- Genome-wide epitope mapping across multiple host species reveals significant diversity in antibody responses toFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 3 countries.
Funding
Abstract
The bacterium
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.